Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-masked Vehicle-controlled Study to Evaluate the Efficacy and Safety of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease

NCT06225973 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.

NCT NCT06225973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-masked Vehicle-controlled Study to Evaluate the Efficacy and Safety of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease
Lead sponsor
Telios Pharma, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
February 6, 2024
Completion date
December 31, 2024
Enrollment
880 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease